Patents Assigned to Xellia Pharmaceuticals ApS
-
Publication number: 20240139278Abstract: The present disclosure relates to a ready-to-administer formulation of oxytocin, its pharmaceutically acceptable salts, or derivatives thereof, as well as products including the formulation. Specifically, the disclosure is directed to storage stable ready-to-administer formulations of oxytocin, method of producing such formulations and uses thereof.Type: ApplicationFiled: December 21, 2023Publication date: May 2, 2024Applicant: XELLIA PHARMACEUTICALS APSInventors: Ivona Jasprica, Marcel Lagedroste
-
Patent number: 11925703Abstract: The present disclosure relates to an aqueous composition stored in a single unit dosage container, where the aqueous composition consists of glucose, sodium bicarbonate, water, and a pH adjusting agent if needed to adjust the pH, wherein the pH of the composition is from 6.7 to 8.1. Such composition is stable for at least 3 months at room temperature conditions.Type: GrantFiled: July 27, 2023Date of Patent: March 12, 2024Assignee: Xellia Pharmaceuticals APSInventors: Barbara Fumic, Stipica Tomic
-
Patent number: 11759497Abstract: The present invention relates to compositions comprising daptomycin and at least one amino acid, methods of providing such compositions and the uses thereof.Type: GrantFiled: August 28, 2018Date of Patent: September 19, 2023Assignee: XELLIA PHARMACEUTICALS APSInventors: Anita Bevetek Mocnik, Stipica Tomic, Barbara Fumic
-
Patent number: 11628200Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.Type: GrantFiled: March 29, 2021Date of Patent: April 18, 2023Assignee: XELLIA PHARMACEUTICALS APSInventors: Ivona Jasprica, Sabina Keser, Katarina Pindric
-
Patent number: 11517609Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.Type: GrantFiled: July 8, 2022Date of Patent: December 6, 2022Assignee: Xellia Pharmaceuticals ApSInventors: Ivona Jasprica, Sabina Keser, Katarina Pindric
-
Publication number: 20220354927Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.Type: ApplicationFiled: July 8, 2022Publication date: November 10, 2022Applicant: Xellia Pharmaceuticals ApSInventors: Ivona Jasprica, Sabina Keser, Katarina Pindric
-
Patent number: 11141417Abstract: Described are voriconazole formulations including 2-hydroxypropyl-?-cyclodextrins and the preparation thereof.Type: GrantFiled: January 24, 2019Date of Patent: October 12, 2021Assignee: XELLIA PHARMACEUTICALS APSInventors: Anita Bevetek Mocnik, Ivona Jasprica, Sasa Grubesic
-
Publication number: 20210220433Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Applicant: Xellia Pharmaceuticals APSInventors: Ivona JASPRICA, Sabina Keser, Katarina Pindric
-
Patent number: 11033602Abstract: Disclosed herein is a pulmonary administration device, comprising a spray nozzle unit and a cartridge containing an aqueous solution comprising from 70 to 400 mg A/m L of a sulfomethylated polymyxin, and use of sulfomethylated polymyxin in a device for pulmonary administration in a patient in need thereof.Type: GrantFiled: October 1, 2015Date of Patent: June 15, 2021Assignee: XELLIA PHARMACEUTICALS APSInventor: Nenad Bencic
-
Patent number: 10933019Abstract: The present invention relates to liquid pharmaceutical compositions comprising daptomycin, methods of providing such compositions and the use thereof. Provided herein are formulations comprising daptomycin, one or more polar protic solvents, and mixtures thereof. Formulations according to the present invention can further comprise polar aprotic solvent and/or source of calcium.Type: GrantFiled: October 17, 2017Date of Patent: March 2, 2021Assignee: XELLIA PHARMACEUTICALS APSInventors: Tina Gjoni, Dubravka Strazic
-
Patent number: 10729708Abstract: Disclosed herein are liquid formulations of glycopeptide antibiotics or pharmaceutically acceptable salts thereof, wherein glycopeptide antibiotic is selected from Vancomycin, Telavancin, Oritavancin, Teicoplanin and Dalbavancin. The formulations are suitable as infusion solutions or as a concentrate for making infusion solutions.Type: GrantFiled: May 4, 2017Date of Patent: August 4, 2020Assignee: Xellia Pharmaceuticals APSInventors: Sabina Keser, Ivona Jasprica, Jerome LeCunff
-
Patent number: 10711040Abstract: The present invention relates to novel low substituted polymyxins and compositions thereof.Type: GrantFiled: June 29, 2015Date of Patent: July 14, 2020Assignee: XELLIA PHARMACEUTICALS APSInventors: Vidar Bjornstad, Solvi Gunnes, Torben Koch, Claes Melander
-
Patent number: 10640536Abstract: Disclosed herein is a composition comprising at least one polymyxin or a salt thereof represented by formula (I) wherein R1 is an aliphatic linear or branched C6-C10 acyl group, or (I?) R5 is —CH(CH3)2, —CH2CH(CH3)2, —CH(CH3)CH2CH3, or —CH2C6H5; R6 is —CH(CH3)2, —CH2CH(CH3)2, or —CH(CH3)CH2CH3; each of R2, R3, R4, R7 and R8 is either —(CH2)xCH2NH2 or —(CH2)xCH2N(CH2SO3M)2; wherein x is 0 or 1; wherein M is a monovalent cation; and wherein at least three of R2, R3, R4, R7 and R8 are —(CH2)xCH2N(CH2SO3M)2.Type: GrantFiled: January 9, 2014Date of Patent: May 5, 2020Assignee: XELLIA PHARMACEUTICALS APSInventors: Solvi Gunnes, Vidar Bjornstad, Torben Koch, Claes Melander, Martin Mansson
-
Patent number: 10532080Abstract: Disclosed herein is an aqueous solution comprising from 80 mg A/mL to 400 mg A/mL of a sulfomethylated polymyxin and a cartridge containing the same. In addition it is disclosed an aqueous solution for use in therapy.Type: GrantFiled: October 1, 2015Date of Patent: January 14, 2020Assignee: XELLIA PHARMACEUTICALS APSInventor: Nenad Bencic
-
Patent number: 10471121Abstract: Disclosed herein is an aqueous solution comprising from 80 mg A/mL to 400 mg A/mL of a sulfomethylated polymyxin and a cartridge containing the same. In addition it is disclosed an aqueous solution for use in therapy.Type: GrantFiled: October 1, 2015Date of Patent: November 12, 2019Assignee: XELLIA PHARMACEUTICALS APSInventor: Nenad Bencic
-
Patent number: 10233514Abstract: A method of dissolution of minerals in acid is disclosed. The method comprises providing minerals to be leached in an aqueous solution, supplying acid or an acid precursor to the aqueous solution, thereby forming a reaction mixture comprising acid; supplying energy in the form of a combination of high-voltage electric pulses and ultrasound pulses to the reaction mixture to enhance dissolution of the minerals.Type: GrantFiled: September 5, 2013Date of Patent: March 19, 2019Assignee: XELLIA PHARMACEUTICALS APSInventors: Ingar F. Walder, Richard Bialecki
-
Patent number: 10227371Abstract: The present invention relates to new polymorphs consisting in crystallines solvates of Tiacumicin B, the solvates being propanol, isopropanol, acetic acid, isopropyl acetate, chlorobenzene and methyl-ethyl-ketone. The present invention also relates to a new amorphous form of Tiacumicin B.Type: GrantFiled: March 17, 2015Date of Patent: March 12, 2019Assignee: XELLIA PHARMACEUTICALS APSInventor: Stefan Kluge
-
Patent number: 10188697Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.Type: GrantFiled: November 6, 2015Date of Patent: January 29, 2019Assignee: XELLIA PHARMACEUTICALS APSInventors: Ivona Jasprica, Sabina Keser, Katarina Pindric
-
Patent number: 10039804Abstract: Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.Type: GrantFiled: November 30, 2017Date of Patent: August 7, 2018Assignee: XELLIA PHARMACEUTICALS APSInventors: Ivona Jasprica, Sabina Keser, Katarina Pindric
-
Patent number: 9393307Abstract: The present invention relates to a composition comprising caspofungin or a pharmaceutical acceptable salt thereof and succinate or lactate as a buffering agent.Type: GrantFiled: November 19, 2014Date of Patent: July 19, 2016Assignee: XELLIA PHARMACEUTICALS APSInventors: Swapnil P. Shirode, Piyush Patel, Suresh Gidwani, Neil Parikh, Atul Patil, Anita Bevetek Mochnik